Compare ADIG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADIG | GHRS |
|---|---|---|
| Founded | 1929 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2026 | 2021 |
| Metric | ADIG | GHRS |
|---|---|---|
| Price | $18.57 | $20.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $26.40 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 451.9K | 303.8K |
| Earning Date | 08-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.99 | N/A |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $12.04 |
| 52 Week High | $30.99 | $31.44 |
| Indicator | ADIG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 47.24 |
| Support Level | N/A | $19.75 |
| Resistance Level | $22.31 | $22.88 |
| Average True Range (ATR) | 0.97 | 1.13 |
| MACD | 0.43 | 0.54 |
| Stochastic Oscillator | 96.61 | 69.72 |
ADI Global Distribution Inc is a specialty distributor of professionally installed low-voltage products, including security and audio-visual (AV) solutions, serving commercial and residential markets through an omnichannel go-to-market platform. It sells to professional installers, dealers, and integrators. The company's product portfolio includes products from third-party suppliers across low-voltage categories, as well as products and services offered under its own brands. Its customer base includes independent contractors, systems integrators, and low-voltage specialists serving business, institutional, and residential end users.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.